Details of Drug-Drug Interaction
| Drug General Information (ID: DDI1MLKIP2) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Phenytoin | Drug Info | Tolazamide | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anticonvulsants | Antidiabetic Agents | |||||||
| Structure | |||||||||
| Mechanism of Phenytoin-Tolazamide Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Antagonize the effect of antidiabetic agents Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Phenytoin | Tolazamide | |||||||
| Mechanism 1 | Hyperglycemia | Antidiabetic agent | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Mechanism 2 | Hyperglycemic effects | Antidiabetic agent | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Antidiabetic agents | ||||||||
| Factor Description | The hypoglycemic effect of antidiabetes may be reduced, leading to higher blood glucose, increased blood glucose fluctuations, and the possibility of hyperglycemic complications | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Consideration should be given to more closely monitoring blood glucose and phenytoin levels during coadministration with sulfonylureas. Patients should be advised to notify their physician if loss of glycemic control occurs or if they experience symptoms of possible phenytoin toxicity, including drowsiness, visual disturbances, change in mental status, seizures, nausea, and ataxia. | ||||||||